EuroNeurotrophin project starts

14 Early Stage Researchers to be trained in a European training network for the discovery of small molecule neurotrophin mimetics as candidate therapeutic agents for neurodegeneration and neuro-inflammation.

Neurodegenerative diseases (ND), like Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis and Motor Neuron Disease, are on the rise with population ageing. Alzheimer’s disease alone affects 36 million people across the world, and 7 million in Europe. The economic burden for ND exceeds 724 billion € and it will reach a trillion euros by 2019. Currently, there is no cure for any ND and most of the available drugs fail to tackle ND pathogenesis.

The EuroNeurotrophin Consortium

Read More